Source: ERS webinar 2020: Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Min Zhou (Shanghai, China), Maxime Patout (Paris, France), Niki Ubags (Lausanne,CH). Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives. ERS webinar 2020: Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives

Member's Comments

No comment yet.

Related content which might interest you: Management of COVID-19: Other drugs and convalescent plasma Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 The efficacy of convalescent plasma therapy in severe COVID-19 patients: a systematic review Source: Virtual Congress 2021 – COVID19, acute respiratory failure and basic science Year: 2021 CVA: serum ECP in the management of steroid therapy Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Association of serum pneumoproteins with clinical course of COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Assessment of serum leptin level in the Egyptian asthmatic patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Other drugs and convalescent plasma Source: Virtual Congress 2020 – Management Year: 2020 Effective anti-tuberculosis therapy correlates with plasma small RNA Source: Eur Respir J 2015; 45: 1741-1744 Year: 2015 Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Compassionate use of bedaquiline in a cohort of Indian drug resistant tuberculosis(DR-TB) patients Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Level of C-reactive protein in blood serum of patients with MDR tuberculosis before and after treatment Source: Eur Respir J 2007; 30: Suppl. 51, 201s Year: 2007 Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Medical treatment and the capacity to deliver multimodality treatment in elderly patients Source: Annual Congress 2011 - Lung cancer management in the elderly Year: 2011 Tuberculosis screening in patients receiving biological therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015 High-dose inhaled corticosteroids and add-on therapy use in adults in the UK: an observational study of 22,027 patients Source: Annual Congress 2004 - Primary care: asthma Year: 2004 Effect of corticosteroid therapy upon serum magnesium level in chronic asthmatic children Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management Year: 2010 Infliximab in patients with refractory sarcoidosis: Trough concentrations of infiximab Source: International Congress 2015 – Clinical problems in acute and chronic lung diseases Year: 2015